For heterozygous familial hypercholesterolemia (HeFH). ANDA 205932, held by Orient Pharma Co Ltd. Pitavastatin Calcium.
As of Nov 16, 2026, ANDA 205932 (Pitavastatin Calcium), held by Orient Pharma Co Ltd, was first approved by FDA on Feb 3, 2017, with 2 approved supplements and 0 published complete response letters.
Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adult with primary hyperlipidemia. Adults with heterozygous familial hypercholesterolemia (HeFH). Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 3, 2017 | Original application | Approved | None posted |
| Pitavastatin CalciumEQ 1MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 2MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 4MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Jun 13, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 4, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 3, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters